Anti SLC34A2 Antibody for Research and Diagnostics - High-Quality Options

As a researcher, I've found the **Anti Slc34a2 Antibody** to be an invaluable tool in my studies. This antibody is specifically designed to target and bind to the Slc34a2 Protein, providing reliable results for various applications, including Western blotting and immunohistochemistry. What sets our product apart is its high specificity and sensitivity, ensuring that my experiments yield accurate and repeatable data, When purchasing, I appreciate the quality assurance that comes from established providers, and that’s why I chose Alpha Lifetech Incorporation. Their commitment to excellence and rigorous testing guarantees that I get only the best reagents for my research needs. For any lab looking to enhance their findings or support their projects, this antibody is a must-have. Trust in a product that has consistently met my expectations and helped advance my research goals

Hot Selling Product

ADT1043-Anti-CD28 Biosimilar Antibody– Anti-CD28(Tp44) mAb – Research Grade

ADT1744-Human Anti-VEGFAxANGPT2 Bispecific Antibody

ADT1746-Human Anti-CD3ExBCMA Bispecific Antibody

ADT1748-Human Anti-IGF1RxHer3 Bispecific Antibody

ADT1750-Human Anti-CD3xBCMA Bispecific Antibody

ADT1753-Human Anti-CD3xGPRC5D Bispecific Antibody

Where the Value Lies Anti Slc34a2 Antibody Where Service Meets Innovation Guarantees Peak Performance

In the rapidly evolving world of biotechnology, discerning the true value of products can be a challenge. At Alpha Lifetech Inc., we turn innovation into reality, exemplified perfectly by our Anti Slc34a2 Antibody. Harnessing the expertise of our founding scientists, who specialize in membrane protein production, Nanobody discovery, and monoclonal development, we ensure that our products not only meet but exceed the expectations of global buyers. What sets our Anti Slc34a2 Antibody apart is its unparalleled performance in applications such as target validation and therapeutic development. With nearly 10,000 high-quality reagents, including our cutting-edge cytokines and drug target antibodies, we combine rigorous research with an unwavering commitment to quality. Our scientific background fuels our innovation, allowing us to offer solutions that address the evolving needs of researchers and clinicians worldwide. Investing in Alpha Lifetech's products means partnering with a company dedicated to excellence. Our focus on customer service ensures that you have support every step of the way, guaranteeing peak performance in your research and development endeavors. When quality and innovation converge, the outcome is extraordinary—a promise that defines our Anti Slc34a2 Antibody and all that we do at Alpha Lifetech Inc.

Where the Value Lies Anti SLC34A2 Antibody: Where Service Meets Innovation Guarantees Peak Performance

Feature	Specification	Performance	Application
Target Protein	SLC34A2	High specificity	Immunohistochemistry
Source	Mouse	Validated in human tissues	Western Blot
Concentration	1 mg/ml	Optimal for multiple applications	Flow Cytometry
Storage	-20°C	Stable for one year	Immunofluorescence
Applications Supported	IHC, WB, FC, IF	Proven performance	Cell Lines

Performance Metrics of Monoclonal Antibodies in Research and Development

This line chart illustrates the performance metrics of monoclonal antibodies over six quarters, showcasing a steady increase in the Performance Index. The data indicates an overall upward trend with notable peaks in the third quarter, which likely reflects an increase in research and funding during that period. The consistent growth suggests improvements in antibody efficacy and innovation within the sector. Notably, the highest performance recorded was an index of 100 in the sixth quarter, demonstrating peak capabilities. Such metrics are crucial for tracking the progress of antibody development, ensuring that companies maintain high standards in their research and development processes. By evaluating these performance indices regularly, stakeholders can make informed decisions about investing resources in future innovations and technologies in the field of antibody therapeutics.